Annalz
2021-12-20
MRNA gonna to fly to another new high
Moderna Says Covid-19 Booster Dose Works Against Omicron Variant in Lab Tests<blockquote>Moderna表示，在实验室测试中，Covid-19加强剂量对奥密克戎病毒变种有效</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":693650502,"tweetId":"693650502","gmtCreate":1640015670540,"gmtModify":1640015671054,"author":{"id":3577089953267281,"idStr":"3577089953267281","authorId":3577089953267281,"authorIdStr":"3577089953267281","name":"Annalz","avatar":"https://static.tigerbbs.com/ffd285ab6189bb61da4b48c3e149eedc","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":45,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>MRNA gonna to fly to another new high</p></body></html>","htmlText":"<html><head></head><body><p>MRNA gonna to fly to another new high</p></body></html>","text":"MRNA gonna to fly to another new high","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/693650502","repostId":1141595302,"repostType":4,"repost":{"id":"1141595302","kind":"news","pubTimestamp":1639997819,"share":"https://www.laohu8.com/m/news/1141595302?lang=zh_CN&edition=full","pubTime":"2021-12-20 18:56","market":"us","language":"en","title":"Moderna Says Covid-19 Booster Dose Works Against Omicron Variant in Lab Tests<blockquote>Moderna表示，在实验室测试中，Covid-19加强剂量对奥密克戎病毒变种有效</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1141595302","media":"WSJ","summary":"ModernaInc. said a third dose of its Covid-19 vaccine increased immune responses against the Omicron","content":"<p>ModernaInc. said a third dose of its Covid-19 vaccine increased immune responses against the Omicron coronavirus variant compared with two doses in lab tests, signaling the shot could still offer protection despite the variant’s mutations.</p><p><blockquote>ModernaInc.表示，与实验室测试中的两剂相比，第三剂Covid-19疫苗增强了针对奥密克戎冠状病毒变种的免疫反应，这表明尽管该变种发生了突变，但该疫苗仍然可以提供保护。</blockquote></p><p> The findings, reported by Moderna on Monday, were the latest positive—though preliminary—results from lab tests suggesting boosters can protect against the worrisome new strain.</p><p><blockquote>Moderna周一报道的这些发现是实验室测试的最新积极结果（尽管是初步结果），表明加强剂可以预防令人担忧的新毒株。</blockquote></p><p> The Cambridge, Mass., company said the authorized dosage of its booster shot increased levels of immune-system agents known as neutralizing antibodies against Omicron about 37 times more than pre-boost levels.</p><p><blockquote>马萨诸塞州剑桥。该公司表示，其加强注射的授权剂量将免疫系统药物（称为奥密克戎中和抗体）的水平提高了约37倍。</blockquote></p><p> Neutralizing antibodies are among the first soldiers that the immune system deploys to battle invaders like the coronavirus.</p><p><blockquote>中和抗体是免疫系统用来对抗冠状病毒等入侵者的第一批士兵之一。</blockquote></p><p> “What we showed is when you boost, you get a good brisk increase in antibody levels and they would be correlated with protection,” Moderna Chief Medical Officer Paul Burton said in an interview.</p><p><blockquote>Moderna首席医疗官保罗·伯顿(Paul Burton)在接受采访时表示：“我们表明，当你加强免疫时，抗体水平会迅速增加，这与保护作用相关。”</blockquote></p><p> The authorized booster shot is half the dose level used for each of the first two shots of the vaccine.</p><p><blockquote>授权的加强注射是疫苗前两次注射所用剂量水平的一半。</blockquote></p><p> Together with similar results from lab testing by Pfizer Inc.and partner BioNTech SE,Moderna’s findings suggest Covid-19 vaccines designed to fight the virus strain that was predominant during 2020may still hold up well against variants such as Omicron that are significantly mutated.</p><p><blockquote>加上辉瑞公司和合作伙伴BioNTech SE实验室测试的类似结果，Moderna的研究结果表明，旨在对抗2020年占主导地位的病毒株病毒的Covid-19疫苗可能仍然可以很好地对抗奥密克戎病毒等显着突变的变种。</blockquote></p><p> Yet people would have to get a booster shot on top of the primary series of vaccinations to gain the protection.</p><p><blockquote>然而，人们必须在初级系列疫苗接种的基础上进行加强注射才能获得保护。</blockquote></p><p> When Omicron emerged, researchers and health authorities expressed concern that the variant could evade vaccines because it has many mutations to the spike protein targeted by the shots.</p><p><blockquote>当奥密克戎病毒出现时，研究人员和卫生当局表示担心该变种可能会逃避疫苗，因为它对疫苗所针对的刺突蛋白有许多突变。</blockquote></p><p> Adding to their fears was research indicating that Omicron is less susceptible to two doses of Moderna’s and other Covid-19 vaccines.</p><p><blockquote>研究表明，奥密克戎不太容易接种两剂Moderna和其他Covid-19疫苗，这加剧了他们的担忧。</blockquote></p><p> Lab-test results released last week by a team of researchers from Moderna, the National Institute of Allergy and Infectious Diseases and Duke University showed that two doses of Moderna’s vaccine had significantly reduced neutralization activity against Omicron.</p><p><blockquote>Moderna、美国国家过敏症和传染病研究所以及杜克大学的一组研究人员上周公布的实验室检测结果显示，两剂Moderna疫苗显著降低了针对奥密克戎的中和活性。</blockquote></p><p> The findings from Pfizer-BioNTech and Moderna are based on lab tests, not the clinical trials in volunteers that are considered more definitive.</p><p><blockquote>辉瑞-BioNTech和Moderna的研究结果是基于实验室测试，而不是被认为更明确的志愿者临床试验。</blockquote></p><p> Moderna disclosed its booster results, which haven’t been peer reviewed and published in a scientific journal, in a news release. The company plans to share the data with government health officials.</p><p><blockquote>Moderna在一份新闻稿中披露了其助推器结果，该结果尚未经过同行评审并发表在科学期刊上。该公司计划与政府卫生官员分享这些数据。</blockquote></p><p> The Omicron variant was identified in late November in southern Africa and has now spread to many countries, including the U.S.</p><p><blockquote>奥密克戎变种于11月下旬在南部非洲被发现，现已传播到包括美国在内的许多国家。</blockquote></p><p> Early studies suggest it spreads faster and reinfects people more easily than other variants and it evades vaccine-induced antibodies to a greater degree. It isn’t known yet whether Omicron causes more or less severe Covid-19.</p><p><blockquote>早期研究表明，它比其他变种传播更快，更容易再次感染人，而且它在更大程度上逃避疫苗诱导的抗体。目前尚不清楚奥密克戎会导致更严重还是更严重的Covid-19。</blockquote></p><p> The new data may reinforce calls by public-health officials for vaccinated people to get booster shots. In the U.S., only about 29.5% of fully vaccinated people have received booster doses, according to the Centers for Disease Control and Prevention.</p><p><blockquote>新数据可能会加强公共卫生官员对接种疫苗的人进行加强注射的评级。根据疾病控制和预防中心的数据，在美国，只有约29.5%的完全接种疫苗的人接受了加强剂量。</blockquote></p><p> Moderna also found that using a full dose for the third shot packed a more powerful punch than the authorized booster dose. A third full dose increased neutralizing antibodies against Omicron about 83 times more than pre-boost levels.</p><p><blockquote>Moderna还发现，使用全剂量进行第三次注射比授权的加强剂量具有更强大的冲击力。第三次全剂量使针对奥密克戎病的中和抗体比加强前水平增加了约83倍。</blockquote></p><p> Dr. Burton said government regulators may want to consider recommending the higher-dose boosters to increase protection, at least among people at higher risk of more severe Covid-19.</p><p><blockquote>伯顿博士说，政府监管机构可能会考虑推荐更高剂量的加强剂来增加保护，至少在更严重的Covid-19风险较高的人群中是这样。</blockquote></p><p> However, in a separate study, Moderna said people receiving the higher-dose booster had more frequent adverse reactions than those who received the lower dose.</p><p><blockquote>然而，在另一项研究中，Moderna表示，接受较高剂量加强剂的人比接受较低剂量的人出现更频繁的不良反应。</blockquote></p><p> Dr. Burton said the reactions include headache, fever and joint stiffness and should be balanced against the potential benefits of a higher-dose booster.</p><p><blockquote>伯顿博士说，这些反应包括头痛、发烧和关节僵硬，应该与更高剂量加强剂的潜在益处相平衡。</blockquote></p><p> Moderna also tested other experimental booster shots that target older variants, including Delta, and found they provided a comparable boost to antibody levels against Omicron as its original vaccine booster shot.</p><p><blockquote>Moderna还测试了其他针对较老变种（包括Delta）的实验性加强注射，发现它们提供的针对奥密克戎病毒的抗体水平与其原始疫苗加强注射相当。</blockquote></p><p> Pfizer and BioNTech said a third dose of their Covid-19 vaccine increased neutralizing antibodies against Omicron compared with just two doses.</p><p><blockquote>辉瑞和BioNTech表示，与仅接种两剂相比，第三剂Covid-19疫苗增加了针对奥密克戎病的中和抗体。</blockquote></p><p> Given the speed of Omicron’s spread, Moderna said its near-term priority will be to continue making booster shots of its original vaccine available.</p><p><blockquote>鉴于奥密克戎病毒传播的速度，Moderna表示，其近期的首要任务将是继续提供其原始疫苗的加强注射。</blockquote></p><p> It said it would keep working on an Omicron-specific booster shot, in case it is needed. Moderna expects to start clinical trials of an Omicron-specific booster in early 2022.</p><p><blockquote>该公司表示，如果需要，将继续研究针对奥密克戎的加强注射。Moderna预计将于2022年初开始奥密克戎病专用加强剂的临床试验。</blockquote></p><p> The new data on Moderna’s booster and Omicron came from lab tests that mix blood samples from vaccinated people with an engineered virus that resembles the Omicron variant. The tests were conducted at Duke University Medical Center labs that were established by the National Institute of Allergy and Infectious Diseases, Moderna said.</p><p><blockquote>关于Moderna加强剂和奥密克戎的新数据来自实验室测试，这些测试将接种疫苗者的血液样本与类似奥密克戎变种的工程病毒混合。Moderna表示，这些测试是在杜克大学医学中心实验室进行的，该实验室由国家过敏和传染病研究所建立。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Says Covid-19 Booster Dose Works Against Omicron Variant in Lab Tests<blockquote>Moderna表示，在实验室测试中，Covid-19加强剂量对奥密克戎病毒变种有效</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Says Covid-19 Booster Dose Works Against Omicron Variant in Lab Tests<blockquote>Moderna表示，在实验室测试中，Covid-19加强剂量对奥密克戎病毒变种有效</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">WSJ</strong><span class=\"h-time small\">2021-12-20 18:56</span>\n</p>\n</h4>\n</header>\n<article>\n<p>ModernaInc. said a third dose of its Covid-19 vaccine increased immune responses against the Omicron coronavirus variant compared with two doses in lab tests, signaling the shot could still offer protection despite the variant’s mutations.</p><p><blockquote>ModernaInc.表示，与实验室测试中的两剂相比，第三剂Covid-19疫苗增强了针对奥密克戎冠状病毒变种的免疫反应，这表明尽管该变种发生了突变，但该疫苗仍然可以提供保护。</blockquote></p><p> The findings, reported by Moderna on Monday, were the latest positive—though preliminary—results from lab tests suggesting boosters can protect against the worrisome new strain.</p><p><blockquote>Moderna周一报道的这些发现是实验室测试的最新积极结果（尽管是初步结果），表明加强剂可以预防令人担忧的新毒株。</blockquote></p><p> The Cambridge, Mass., company said the authorized dosage of its booster shot increased levels of immune-system agents known as neutralizing antibodies against Omicron about 37 times more than pre-boost levels.</p><p><blockquote>马萨诸塞州剑桥。该公司表示，其加强注射的授权剂量将免疫系统药物（称为奥密克戎中和抗体）的水平提高了约37倍。</blockquote></p><p> Neutralizing antibodies are among the first soldiers that the immune system deploys to battle invaders like the coronavirus.</p><p><blockquote>中和抗体是免疫系统用来对抗冠状病毒等入侵者的第一批士兵之一。</blockquote></p><p> “What we showed is when you boost, you get a good brisk increase in antibody levels and they would be correlated with protection,” Moderna Chief Medical Officer Paul Burton said in an interview.</p><p><blockquote>Moderna首席医疗官保罗·伯顿(Paul Burton)在接受采访时表示：“我们表明，当你加强免疫时，抗体水平会迅速增加，这与保护作用相关。”</blockquote></p><p> The authorized booster shot is half the dose level used for each of the first two shots of the vaccine.</p><p><blockquote>授权的加强注射是疫苗前两次注射所用剂量水平的一半。</blockquote></p><p> Together with similar results from lab testing by Pfizer Inc.and partner BioNTech SE,Moderna’s findings suggest Covid-19 vaccines designed to fight the virus strain that was predominant during 2020may still hold up well against variants such as Omicron that are significantly mutated.</p><p><blockquote>加上辉瑞公司和合作伙伴BioNTech SE实验室测试的类似结果，Moderna的研究结果表明，旨在对抗2020年占主导地位的病毒株病毒的Covid-19疫苗可能仍然可以很好地对抗奥密克戎病毒等显着突变的变种。</blockquote></p><p> Yet people would have to get a booster shot on top of the primary series of vaccinations to gain the protection.</p><p><blockquote>然而，人们必须在初级系列疫苗接种的基础上进行加强注射才能获得保护。</blockquote></p><p> When Omicron emerged, researchers and health authorities expressed concern that the variant could evade vaccines because it has many mutations to the spike protein targeted by the shots.</p><p><blockquote>当奥密克戎病毒出现时，研究人员和卫生当局表示担心该变种可能会逃避疫苗，因为它对疫苗所针对的刺突蛋白有许多突变。</blockquote></p><p> Adding to their fears was research indicating that Omicron is less susceptible to two doses of Moderna’s and other Covid-19 vaccines.</p><p><blockquote>研究表明，奥密克戎不太容易接种两剂Moderna和其他Covid-19疫苗，这加剧了他们的担忧。</blockquote></p><p> Lab-test results released last week by a team of researchers from Moderna, the National Institute of Allergy and Infectious Diseases and Duke University showed that two doses of Moderna’s vaccine had significantly reduced neutralization activity against Omicron.</p><p><blockquote>Moderna、美国国家过敏症和传染病研究所以及杜克大学的一组研究人员上周公布的实验室检测结果显示，两剂Moderna疫苗显著降低了针对奥密克戎的中和活性。</blockquote></p><p> The findings from Pfizer-BioNTech and Moderna are based on lab tests, not the clinical trials in volunteers that are considered more definitive.</p><p><blockquote>辉瑞-BioNTech和Moderna的研究结果是基于实验室测试，而不是被认为更明确的志愿者临床试验。</blockquote></p><p> Moderna disclosed its booster results, which haven’t been peer reviewed and published in a scientific journal, in a news release. The company plans to share the data with government health officials.</p><p><blockquote>Moderna在一份新闻稿中披露了其助推器结果，该结果尚未经过同行评审并发表在科学期刊上。该公司计划与政府卫生官员分享这些数据。</blockquote></p><p> The Omicron variant was identified in late November in southern Africa and has now spread to many countries, including the U.S.</p><p><blockquote>奥密克戎变种于11月下旬在南部非洲被发现，现已传播到包括美国在内的许多国家。</blockquote></p><p> Early studies suggest it spreads faster and reinfects people more easily than other variants and it evades vaccine-induced antibodies to a greater degree. It isn’t known yet whether Omicron causes more or less severe Covid-19.</p><p><blockquote>早期研究表明，它比其他变种传播更快，更容易再次感染人，而且它在更大程度上逃避疫苗诱导的抗体。目前尚不清楚奥密克戎会导致更严重还是更严重的Covid-19。</blockquote></p><p> The new data may reinforce calls by public-health officials for vaccinated people to get booster shots. In the U.S., only about 29.5% of fully vaccinated people have received booster doses, according to the Centers for Disease Control and Prevention.</p><p><blockquote>新数据可能会加强公共卫生官员对接种疫苗的人进行加强注射的评级。根据疾病控制和预防中心的数据，在美国，只有约29.5%的完全接种疫苗的人接受了加强剂量。</blockquote></p><p> Moderna also found that using a full dose for the third shot packed a more powerful punch than the authorized booster dose. A third full dose increased neutralizing antibodies against Omicron about 83 times more than pre-boost levels.</p><p><blockquote>Moderna还发现，使用全剂量进行第三次注射比授权的加强剂量具有更强大的冲击力。第三次全剂量使针对奥密克戎病的中和抗体比加强前水平增加了约83倍。</blockquote></p><p> Dr. Burton said government regulators may want to consider recommending the higher-dose boosters to increase protection, at least among people at higher risk of more severe Covid-19.</p><p><blockquote>伯顿博士说，政府监管机构可能会考虑推荐更高剂量的加强剂来增加保护，至少在更严重的Covid-19风险较高的人群中是这样。</blockquote></p><p> However, in a separate study, Moderna said people receiving the higher-dose booster had more frequent adverse reactions than those who received the lower dose.</p><p><blockquote>然而，在另一项研究中，Moderna表示，接受较高剂量加强剂的人比接受较低剂量的人出现更频繁的不良反应。</blockquote></p><p> Dr. Burton said the reactions include headache, fever and joint stiffness and should be balanced against the potential benefits of a higher-dose booster.</p><p><blockquote>伯顿博士说，这些反应包括头痛、发烧和关节僵硬，应该与更高剂量加强剂的潜在益处相平衡。</blockquote></p><p> Moderna also tested other experimental booster shots that target older variants, including Delta, and found they provided a comparable boost to antibody levels against Omicron as its original vaccine booster shot.</p><p><blockquote>Moderna还测试了其他针对较老变种（包括Delta）的实验性加强注射，发现它们提供的针对奥密克戎病毒的抗体水平与其原始疫苗加强注射相当。</blockquote></p><p> Pfizer and BioNTech said a third dose of their Covid-19 vaccine increased neutralizing antibodies against Omicron compared with just two doses.</p><p><blockquote>辉瑞和BioNTech表示，与仅接种两剂相比，第三剂Covid-19疫苗增加了针对奥密克戎病的中和抗体。</blockquote></p><p> Given the speed of Omicron’s spread, Moderna said its near-term priority will be to continue making booster shots of its original vaccine available.</p><p><blockquote>鉴于奥密克戎病毒传播的速度，Moderna表示，其近期的首要任务将是继续提供其原始疫苗的加强注射。</blockquote></p><p> It said it would keep working on an Omicron-specific booster shot, in case it is needed. Moderna expects to start clinical trials of an Omicron-specific booster in early 2022.</p><p><blockquote>该公司表示，如果需要，将继续研究针对奥密克戎的加强注射。Moderna预计将于2022年初开始奥密克戎病专用加强剂的临床试验。</blockquote></p><p> The new data on Moderna’s booster and Omicron came from lab tests that mix blood samples from vaccinated people with an engineered virus that resembles the Omicron variant. The tests were conducted at Duke University Medical Center labs that were established by the National Institute of Allergy and Infectious Diseases, Moderna said.</p><p><blockquote>关于Moderna加强剂和奥密克戎的新数据来自实验室测试，这些测试将接种疫苗者的血液样本与类似奥密克戎变种的工程病毒混合。Moderna表示，这些测试是在杜克大学医学中心实验室进行的，该实验室由国家过敏和传染病研究所建立。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.wsj.com/articles/moderna-says-covid-19-booster-dose-works-against-omicron-variant-in-lab-tests-11639994403?mod=hp_lead_pos2\">WSJ</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.wsj.com/articles/moderna-says-covid-19-booster-dose-works-against-omicron-variant-in-lab-tests-11639994403?mod=hp_lead_pos2","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1141595302","content_text":"ModernaInc. said a third dose of its Covid-19 vaccine increased immune responses against the Omicron coronavirus variant compared with two doses in lab tests, signaling the shot could still offer protection despite the variant’s mutations.\nThe findings, reported by Moderna on Monday, were the latest positive—though preliminary—results from lab tests suggesting boosters can protect against the worrisome new strain.\nThe Cambridge, Mass., company said the authorized dosage of its booster shot increased levels of immune-system agents known as neutralizing antibodies against Omicron about 37 times more than pre-boost levels.\nNeutralizing antibodies are among the first soldiers that the immune system deploys to battle invaders like the coronavirus.\n“What we showed is when you boost, you get a good brisk increase in antibody levels and they would be correlated with protection,” Moderna Chief Medical Officer Paul Burton said in an interview.\nThe authorized booster shot is half the dose level used for each of the first two shots of the vaccine.\nTogether with similar results from lab testing by Pfizer Inc.and partner BioNTech SE,Moderna’s findings suggest Covid-19 vaccines designed to fight the virus strain that was predominant during 2020may still hold up well against variants such as Omicron that are significantly mutated.\nYet people would have to get a booster shot on top of the primary series of vaccinations to gain the protection.\nWhen Omicron emerged, researchers and health authorities expressed concern that the variant could evade vaccines because it has many mutations to the spike protein targeted by the shots.\nAdding to their fears was research indicating that Omicron is less susceptible to two doses of Moderna’s and other Covid-19 vaccines.\nLab-test results released last week by a team of researchers from Moderna, the National Institute of Allergy and Infectious Diseases and Duke University showed that two doses of Moderna’s vaccine had significantly reduced neutralization activity against Omicron.\nThe findings from Pfizer-BioNTech and Moderna are based on lab tests, not the clinical trials in volunteers that are considered more definitive.\nModerna disclosed its booster results, which haven’t been peer reviewed and published in a scientific journal, in a news release. The company plans to share the data with government health officials.\nThe Omicron variant was identified in late November in southern Africa and has now spread to many countries, including the U.S.\nEarly studies suggest it spreads faster and reinfects people more easily than other variants and it evades vaccine-induced antibodies to a greater degree. It isn’t known yet whether Omicron causes more or less severe Covid-19.\nThe new data may reinforce calls by public-health officials for vaccinated people to get booster shots. In the U.S., only about 29.5% of fully vaccinated people have received booster doses, according to the Centers for Disease Control and Prevention.\nModerna also found that using a full dose for the third shot packed a more powerful punch than the authorized booster dose. A third full dose increased neutralizing antibodies against Omicron about 83 times more than pre-boost levels.\nDr. Burton said government regulators may want to consider recommending the higher-dose boosters to increase protection, at least among people at higher risk of more severe Covid-19.\nHowever, in a separate study, Moderna said people receiving the higher-dose booster had more frequent adverse reactions than those who received the lower dose.\nDr. Burton said the reactions include headache, fever and joint stiffness and should be balanced against the potential benefits of a higher-dose booster.\nModerna also tested other experimental booster shots that target older variants, including Delta, and found they provided a comparable boost to antibody levels against Omicron as its original vaccine booster shot.\nPfizer and BioNTech said a third dose of their Covid-19 vaccine increased neutralizing antibodies against Omicron compared with just two doses.\nGiven the speed of Omicron’s spread, Moderna said its near-term priority will be to continue making booster shots of its original vaccine available.\nIt said it would keep working on an Omicron-specific booster shot, in case it is needed. Moderna expects to start clinical trials of an Omicron-specific booster in early 2022.\nThe new data on Moderna’s booster and Omicron came from lab tests that mix blood samples from vaccinated people with an engineered virus that resembles the Omicron variant. The tests were conducted at Duke University Medical Center labs that were established by the National Institute of Allergy and Infectious Diseases, Moderna said.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":1941,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":30,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/693650502"}
精彩评论